Levetiracetam
Product Images NDC 53808-0376

8 FDA label images from State Of Florida Doh Central Pharmacy · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 53808-0376). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Levetiractam Structural Formula (3df96d02 Dd76 4b97 A189 Bc69c1e6c08d 01)

Levetiractam Structural Formula (3df96d02 Dd76 4b97 A189 Bc69c1e6c08d 01)
Chemical structure of Levetiracetam showing a pyrrolidone ring attached to an amino acid side chain with a methyl and ethyl group.*
FDA Label Image

Figure 1: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 1 (3df96d02 Dd76 4b97 A189 Bc69c1e6c08d 02)

Figure 1: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 1 (3df96d02 Dd76 4b97 A189 Bc69c1e6c08d 02)
A bar graph comparing the percentage of patients in three groups: Placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%). The vertical axis represents percentage of patients from 0% to 45%. Values for Levetiracetam groups are noted as statistically significant versus placebo.*
FDA Label Image

Figure 2: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 2: Period A (3df96d02 Dd76 4b97 A189 Bc69c1e6c08d 03)

Figure 2: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 2: Period A (3df96d02 Dd76 4b97 A189 Bc69c1e6c08d 03)
A bar graph comparing the percentage of patients across three groups: placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The y-axis represents the percentage of patients, with Levetiracetam at 1000 mg/day showing about 20.8%, Levetiracetam at 2000 mg/day about 35.2%, and placebo about 6.3%, with a note indicating statistical significance versus placebo.*
FDA Label Image

Figure 3: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 3 (3df96d02 Dd76 4b97 A189 Bc69c1e6c08d 04)

Figure 3: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 3 (3df96d02 Dd76 4b97 A189 Bc69c1e6c08d 04)
A bar chart comparing the percentage of patients in two groups: Placebo (104 patients) and Levetiracetam 3000 mg/day (180 patients). The y-axis shows percentage of patients from 0% to 45%. The Levetiracetam group shows a higher percentage (39.4%) compared to the Placebo group (14.4%), with an asterisk indicating statistical significance versus placebo.*
FDA Label Image

Figure 4: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) (3df96d02 Dd76 4b97 A189 Bc69c1e6c08d 05)

Figure 4: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) (3df96d02 Dd76 4b97 A189 Bc69c1e6c08d 05)
A bar chart comparing the percentage of patients experiencing a response between placebo and levetiracetam groups. The placebo group shows 19.6% (N=97) and the levetiracetam group shows 44.6% (N=101), with a note indicating statistical significance versus placebo.*
FDA Label Image

Pediatric Patient Oral Solution Calculation (3df96d02 Dd76 4b97 A189 Bc69c1e6c08d 06)

Pediatric Patient Oral Solution Calculation (3df96d02 Dd76 4b97 A189 Bc69c1e6c08d 06)
Mathematical formula showing calculation for total daily dose in mL/day as patient weight (kg) times daily dose (mg/kg/day) divided by 100 mg/mL concentration.*
FDA Label Image

Creatinine Clearance Calculation (3df96d02 Dd76 4b97 A189 Bc69c1e6c08d 07)

Creatinine Clearance Calculation (3df96d02 Dd76 4b97 A189 Bc69c1e6c08d 07)
An illustration showing the formula for creatinine clearance (CLcr) calculation. The formula uses age in years, weight in kilograms, and serum creatinine in mg/dL, with a multiplier of 0.85 for female patients.*
FDA Label Image

Levetiracetam Tablets 500 mg Bottles (Levetiracetam 500mg(mylan))

Levetiracetam Tablets 500 mg Bottles (Levetiracetam 500mg(mylan))
Levetiracetam 500 mg tablets prescription label by State of Florida DOH Central Pharmacy. The label indicates a quantity of 30 tablets, with manufacturer Mylan. It includes lot number 3014392 and an expiration date of August 31, 2010. The label also shows usage as RX only and contains a UPC barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.